Diabetic Macular Edema – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Diabetic Macular Edema – Pipeline Review, H1 2020’, provides an overview of the Diabetic Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema

– The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Abpro Corp

Aciont Inc

Acucela Inc

Aerie Pharmaceuticals Inc

Aerpio Pharmaceuticals Inc

Aldeyra Therapeutics Inc

Allegro Ophthalmics LLC

Allergan Plc

Allgenesis Biotherapeutics Inc

Ampio Pharmaceuticals Inc

Apexian Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Ascentage Pharma Group International

AsclepiX Therapeutics Inc

BetaStem Therapeutics Inc

Bio-Thera Solutions Ltd

Boehringer Ingelheim International GmbH

Cell Care Therapeutics Inc

Cell Medica Ltd

Celon Pharma SA

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Chiome Bioscience Inc

Clearside BioMedical Inc

Coherus BioSciences Inc

Elasmogen Ltd

Eleusis Ltd

Everglades Biopharma LLC

Exonate Ltd

EyeGate Pharmaceuticals Inc

Eyevensys SAS

F. Hoffmann-La Roche Ltd

Formycon AG

Gene Signal International SA

Graybug Vision Inc

Isarna Therapeutics GmbH

Kalvista Pharmaceuticals Inc

Kodiak Sciences Inc

Kowa Co Ltd

Lupin Ltd

Luye Pharma Group Ltd

Mabion SA

Momenta Pharmaceuticals Inc

NeuBase Therapeutics Inc

NeuMedics Inc

Novartis AG

Novelty Nobility Inc

OccuRx Pty Ltd

Ocugen Inc

Ocular Therapeutix Inc

Oculis SA

OcuNexus Therapeutics Inc

Opthea Ltd

Outlook Therapeutics Inc

Oxurion NV

Pfizer Inc

Phanes Therapeutics Inc

PharmAbcine Inc

Pleryon Therapeutics Ltd

Profarma

Protheragen Inc

Qilu Pharmaceutical Co Ltd

RemeGen Ltd

Rezolute Inc

RiniSight Inc

SciFluor Life Sciences LLC

Semathera Inc

Senju Pharmaceutical Co Ltd

Suzhou Stainwei Biotech Inc

Targeted Therapy Technologies LLC

Theravance Biopharma Inc

Verseon Corp

Xbrane Biopharma AB

YD Life Science Co

Table of Contents

Table of Contents

Introduction

Diabetic Macular Edema - Overview

Diabetic Macular Edema - Therapeutics Development

Diabetic Macular Edema - Therapeutics Assessment

Diabetic Macular Edema - Companies Involved in Therapeutics Development

Diabetic Macular Edema - Drug Profiles

Diabetic Macular Edema - Dormant Projects

Diabetic Macular Edema - Discontinued Products

Diabetic Macular Edema - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Diabetic Macular Edema, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Diabetic Macular Edema – Pipeline by 3SBio Inc, H1 2020

Diabetic Macular Edema – Pipeline by Abpro Corp, H1 2020

Diabetic Macular Edema – Pipeline by Aciont Inc, H1 2020

Diabetic Macular Edema – Pipeline by Acucela Inc, H1 2020

Diabetic Macular Edema – Pipeline by Aerie Pharmaceuticals Inc, H1 2020

Diabetic Macular Edema – Pipeline by Aerpio Pharmaceuticals Inc, H1 2020

Diabetic Macular Edema – Pipeline by Aldeyra Therapeutics Inc, H1 2020

Diabetic Macular Edema – Pipeline by Allegro Ophthalmics LLC, H1 2020

Diabetic Macular Edema – Pipeline by Allergan Plc, H1 2020

Diabetic Macular Edema – Pipeline by Allgenesis Biotherapeutics Inc, H1 2020

Diabetic Macular Edema – Pipeline by Ampio Pharmaceuticals Inc, H1 2020

Diabetic Macular Edema – Pipeline by Apexian Pharmaceuticals Inc, H1 2020

Diabetic Macular Edema – Pipeline by Araim Pharmaceuticals Inc, H1 2020

Diabetic Macular Edema – Pipeline by Ascentage Pharma Group International, H1 2020

Diabetic Macular Edema – Pipeline by AsclepiX Therapeutics Inc, H1 2020

Diabetic Macular Edema – Pipeline by BetaStem Therapeutics Inc, H1 2020

Diabetic Macular Edema – Pipeline by Bio-Thera Solutions Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Diabetic Macular Edema – Pipeline by Cell Care Therapeutics Inc, H1 2020

Diabetic Macular Edema – Pipeline by Cell Medica Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Celon Pharma SA, H1 2020

Diabetic Macular Edema – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Chiome Bioscience Inc, H1 2020

Diabetic Macular Edema – Pipeline by Clearside BioMedical Inc, H1 2020

Diabetic Macular Edema – Pipeline by Coherus BioSciences Inc, H1 2020

Diabetic Macular Edema – Pipeline by Elasmogen Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Eleusis Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Everglades Biopharma LLC, H1 2020

Diabetic Macular Edema – Pipeline by Exonate Ltd, H1 2020

Diabetic Macular Edema – Pipeline by EyeGate Pharmaceuticals Inc, H1 2020

Diabetic Macular Edema – Pipeline by Eyevensys SAS, H1 2020

Diabetic Macular Edema – Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Formycon AG, H1 2020

Diabetic Macular Edema – Pipeline by Gene Signal International SA, H1 2020

Diabetic Macular Edema – Pipeline by Graybug Vision Inc, H1 2020

Diabetic Macular Edema – Pipeline by Isarna Therapeutics GmbH, H1 2020

Diabetic Macular Edema – Pipeline by Kalvista Pharmaceuticals Inc, H1 2020

Diabetic Macular Edema – Pipeline by Kodiak Sciences Inc, H1 2020

Diabetic Macular Edema – Pipeline by Kowa Co Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Lupin Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Luye Pharma Group Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Mabion SA, H1 2020

Diabetic Macular Edema – Pipeline by Momenta Pharmaceuticals Inc, H1 2020

Diabetic Macular Edema – Pipeline by NeuBase Therapeutics Inc, H1 2020

Diabetic Macular Edema – Pipeline by NeuMedics Inc, H1 2020

Diabetic Macular Edema – Pipeline by Novartis AG, H1 2020

Diabetic Macular Edema – Pipeline by Novelty Nobility Inc, H1 2020

Diabetic Macular Edema – Pipeline by OccuRx Pty Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Ocugen Inc, H1 2020

Diabetic Macular Edema – Pipeline by Ocular Therapeutix Inc, H1 2020

Diabetic Macular Edema – Pipeline by Oculis SA, H1 2020

Diabetic Macular Edema – Pipeline by OcuNexus Therapeutics Inc, H1 2020

Diabetic Macular Edema – Pipeline by Opthea Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Outlook Therapeutics Inc, H1 2020

Diabetic Macular Edema – Pipeline by Oxurion NV, H1 2020

Diabetic Macular Edema – Pipeline by Pfizer Inc, H1 2020

Diabetic Macular Edema – Pipeline by Phanes Therapeutics Inc, H1 2020

Diabetic Macular Edema – Pipeline by PharmAbcine Inc, H1 2020

Diabetic Macular Edema – Pipeline by Pleryon Therapeutics Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Profarma, H1 2020

Diabetic Macular Edema – Pipeline by Protheragen Inc, H1 2020

Diabetic Macular Edema – Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020

Diabetic Macular Edema – Pipeline by RemeGen Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Rezolute Inc, H1 2020

Diabetic Macular Edema – Pipeline by RiniSight Inc, H1 2020

Diabetic Macular Edema – Pipeline by SciFluor Life Sciences LLC, H1 2020

Diabetic Macular Edema – Pipeline by Semathera Inc, H1 2020

Diabetic Macular Edema – Pipeline by Senju Pharmaceutical Co Ltd, H1 2020

Diabetic Macular Edema – Pipeline by Suzhou Stainwei Biotech Inc, H1 2020

Diabetic Macular Edema – Pipeline by Targeted Therapy Technologies LLC, H1 2020

Diabetic Macular Edema – Pipeline by Theravance Biopharma Inc, H1 2020

Diabetic Macular Edema – Pipeline by Verseon Corp, H1 2020

Diabetic Macular Edema – Pipeline by Xbrane Biopharma AB, H1 2020

Diabetic Macular Edema – Pipeline by YD Life Science Co, H1 2020

Diabetic Macular Edema – Dormant Projects, H1 2020

Diabetic Macular Edema – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Diabetic Macular Edema, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports